CAMBRIDGE, Mass., Feb. 24 /PRNewswire/ -- Gene Network Sciences, Inc. (GNS) today announced that it has named Michael Gilman, Ph.D., Founder and Chief Executive Officer of Stromedix, Inc. and former Executive Vice President of Research at Biogen Idec, to its Board of Directors.
Dr. Gilman has been Founder and Chief Executive Officer of Stromedix since June 2006. He was previously Executive Vice President, Research at Biogen Idec. He joined Biogen in 1999 as Director of Molecular Biology and became head of research at Biogen in 2000. From 1994 to 1999, Dr. Gilman held several positions at ARIAD Pharmaceuticals, including Executive Vice President and Chief Scientific Officer. Prior to that, Dr. Gilman spent eight years on the scientific staff of Cold Spring Harbor Laboratory in New York, where his research focused on mechanisms of signal transduction and gene regulation. Dr. Gilman holds a Ph.D. in Biochemistry from
"Michael Gilman's broad pharma research leadership experience will play a critical role in GNS's effectively deploying our REFS(TM) platform to accelerate pharma drug research and development," said Colin Hill, CEO of GNS. "I am looking forward to leveraging his experiences to create maximum impact for our partners."
"I was drawn to GNS by the power of the supercomputer-driven REFS(TM) platform to enable both new forms of discovery and new approaches to personalized medicine. The industry is at a crossroads, with advances in DNA sequencing finally paving the way to a more systematic exploration of disease biology and drug response markers. Data is no longer the bottleneck -- the analysis is. That's why I see technology such as GNS's as the missing link," said Dr. Gilman.
About Gene Network Sciences
Gene Network Sciences (http://www.gnsbiotech.com/) is a leader in biosimulation with its ability to derive molecular mechanisms of drugs and diseases directly from molecular profiling and clinical data. Based in Cambridge, Massachusetts, and Ithaca, New York, GNS uses its REFS(TM) technology in pharmaceutical and clinical settings to rapidly turn combinations of genetic, genomic, and clinical measurements into models of disease progression and drug response. These models are then simulated to discover both new targets for drug intervention and genetic markers of drug response that allow patients who will respond to a given drug treatment to be matched to a particular clinical trial. By discovering how and why specific sets of genes and drug candidates impact human biology, GNS technology enables the rapid development of breakthrough drug and diagnostic products.
|SOURCE Gene Network Sciences, Inc.|
Copyright©2009 PR Newswire.
All rights reserved